Checkmate Pharmaceuticals Overview
Checkmate Pharmaceuticals (CMPI) has a P/E ratio of -3.7, below the Healthcare sector average of 27.22.
Get informed when a big investor buys or sells
+ Follow-3.70
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for CMPI is -3.7. That is below the Healthcare sector average of 27.22. Investors often review this figure alongside Checkmate Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CMPI currently prints -3.7 for P/E ratio, while the sector average sits near 27.22. That is roughly 113.6% below the sector mean. Large gaps often invite a closer look at Checkmate Pharmaceuticals's growth, margins, and balance sheet.
A P/E ratio of -3.7 for Checkmate Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (27.22) and with CMPI's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CMPI's P/E ratio (-3.7), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Checkmate Pharmaceuticals's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
